Sunshine Lake Pharma Co., Ltd. clinical trial pipeline

5 trials changed in the last 30 days: 2 stopped, 2 with notable changes, 1 with a minor change only.

1. Stopped

   HEC169096 · Advanced Solid Tumors

   Trial terminated

   Also in this update: Final enrollment: 24 participants — 5% of the 456 planned; Primary completion date changed from estimate of Dec 30, 2026 to Sep 23, 2025

   Sunshine Lake Pharma Co., Ltd.·Phase 1/2· NCT05451602· Registry history of NCT05451602 on ClinicalTrials.gov (opens the registry)

   Oct 14, 2026

2. Stopped

   Larotinib · Impaired Hepatic Function

   Withdrawn before enrolling

   Sunshine Lake Pharma Co., Ltd.·Phase 1· NCT05048368· Registry history of NCT05048368 on ClinicalTrials.gov (opens the registry)

   Sep 28, 2026

3. Notable

   Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer

   Primary completion pushed from Aug 2026 to Aug 2027

   Also in this update: Study completion pushed from Dec 30, 2026 to Dec 30, 2027

   Sunshine Lake Pharma Co., Ltd.·Phase 3· NCT04415853· Registry history of NCT04415853 on ClinicalTrials.gov (opens the registry)

   Sep 28, 2026

4. Notable

   HEC-921 Injection as Monotherapy and in Combination With…HEC-921 Injection as Monotherapy and in Combination With Antineoplastic Therapies · Advanced Malignant Solid Tumors

   Recruitment opened

   Sunshine Lake Pharma Co., Ltd.·Phase 1· NCT07824934· Registry history of NCT07824934 on ClinicalTrials.gov (opens the registry)

   Sep 24, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.